Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis

Annals of Noninvasive Electrocardiology

Volumn 16, Issue 2, 2011, Pages 140-147

  Yodogawa, Kenji ^a   Seino, Yoshihiko ^a   Ohara, Toshihiko ^b   Takayama, Hideo ^b   Katoh, Takao ^b   Mizuno, Kyoichi ^b  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

cardiac sarcoidosis; corticosteroid; ventricular arrhythmia

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; GALLIUM 67; PREDNISONE;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG UPTAKE; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; MAINTENANCE DRUG DOSE; MALE; PREVALENCE; PRIORITY JOURNAL; SARCOIDOSIS; SCINTIGRAPHY; SIGNAL AVERAGED ELECTROCARDIOGRAPHY;

ADRENAL CORTEX HORMONES; BIOLOGICAL MARKERS; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOIDOSIS; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR PREMATURE COMPLEXES;

EID: 79955055476     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2011.00418.x     Document Type: Article

References (28)

1. Newman LE, Rose CS, Maier LA,. Sarcoidosis. N Engl J Med 1997; 336: 1224-1234. (Pubitemid 27183653)
2. Yazaki Y, Isobe M, Hiroe M, et al,. Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisolone. Am J Cardiol 2001; 88: 1006-1010. (Pubitemid 33042612)
3. Chiu CZ, Nakatani S, Zhang G, et al,. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005; 95: 143-146. (Pubitemid 40051133)
4. Doval HC, Nul DR, Grancelli HO, et al,. Nonsustained ventricular tachycardia in severe heart failure: Independent marker of increased mortality due to sudden death: GESICA-GEMA Investigators. Circulation 1996; 94: 3198-3203. (Pubitemid 26427487)
5. Grimm W, Glaveris C, Hoffmann J, et al,. Arrhythmia risk stratification in idiopathic dilated cardiomyopathy based on echocardiography and 12-lead, signal-averaged, and 24-hour holter electrocardiography. Am Heart J 2000; 140: 43-51. (Pubitemid 30471240)
6. Monserrat L, Elliott PM, Gimeno JR, et al,. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42: 873-879. (Pubitemid 37059747)
7. Hiraga H, Yuwai K, Hiroe M,. Guideline for diagnosis of cardiac sarcoidosis: Study report on diffuse pulmonary disease from the Japanese Ministry of Health and Welfare (in Japanese). 1993; 6: 23-24.
8. Smedema JP, Snoep G, van Kroonenburgh MP, et al,. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45: 1683-1690. (Pubitemid 40704507)
9. Patel MR, Cawley PJ, Heitner JF, et al,. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009; 120: 1969-1977.
10. Gomes JA, Winters SL, Martinson M, et al,. The prognostic significance of quantitative signal-averaged variables relative to clinical variables, site of myocardial infarction, ejection fraction and ventricular premature beats: A prospective study. J Am Coll Cardiol 1989; 13: 377-384. (Pubitemid 19055662)
11. Kasahara Y, Ashihara Y,. Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem 1981; 27: 1922-1925. (Pubitemid 12228558)
12. Hiramitsu S, Morimoto S, Uemura A, et al,. National survey on status of steroid therapy for cardiac sarcoidosis in Japan. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: 210-213. (Pubitemid 41670613)
13. Kato Y, Morimoto S, Uemura A, et al,. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis. 2003; 20: 133-137. (Pubitemid 36841694)
14. Umetani K, Ishihara T, Yamamoto K, et al,. Successfully treated complete atrioventricular block with corticosteroid in a patient with cardiac sarcoidosis: Usefulness of Gallium-67 and Thallium-201 scintigraphy. Int Med 2000; 39: 245-248. (Pubitemid 30204918)
15. Sugishita K, Togashi Y, Aizawa A, et al,. Postpartum complete atrioventricular block due to cardiac sarcoidosis. Steroid therapy without permanent pacemaker. Int Heart J 2008; 49: 377-384.
16. Walsh MJ,. Systemic sarcoidosis with refractory ventricular tachycardia and heart failure. Br Heart J 1978; 40: 931-933. (Pubitemid 9011137)
17. Winters SL, Cohen M, Greenberg S, et al,. Sustained ventricular tachycardia associated with sarcoidosis: Assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol 1991; 18: 937-943.
18. Uusimaa P, Ylitalo, K, Anttonen O, et al,. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace 2008; 10: 760-766. (Pubitemid 351775278)
19. Banba K, Kusano KF, Nakamura K, et al,. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm 2007; 4: 1292-1299. (Pubitemid 47457196)
20. Okayama K, Kurata C, Tawarahara K, et al,. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 1995; 107: 330-334.
21. Shimada T, Shimada K, Sakane T, et al,. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001; 110: 520-527.
22. Okumura W, Iwasaki T, Toyama T, et al,. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004; 45: 1989-1998. (Pubitemid 47611626)
23. Yasutake H, Seino Y, Kashiwagi M, et al,. Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol 2005; 102: 259-268.2288;2288;2288. (Pubitemid 40854040)
24. Futamatsu H, Suzuki J, Adachi S, et al,. Utility of gallium-67 scintigraphy for evaluation of cardiac sarcoidosis with ventricular tachycardia. Int J Cardiovasc Imaging 2006; 22: 443-448. (Pubitemid 43880675)
25. Casset-Senon D, Philippe L, Renard JP, et al,. Recurrent ventricular tachycardia in cardiac sarcoidosis: Usefulness of fluorodeoxyglucose positron emission tomography for adequate management of corticoid therapy after placement of an implantable cardioverter defibrillator. J Nucl Cardiol 2008; 15: 282-285. (Pubitemid 351409244)
26. Yodogawa K, Seino Y, Ohara T, et al,. Non-invasive detection of latent cardiac conduction abnormalities in patients with pulmonary sarcoidosis. Circ J. 2007; 71: 540-545. (Pubitemid 46513462)
27. The ESVEM Investigators. The ESVEM trial: Electrophysiologic study versus electrocardiographic monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. Circulation 1989; 79: 1354-1360.
28. Epstein AE, DiMarco JP, Ellenbogen KA, et al,. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117: 350-408.